Schedule an Appointment
Wellesley Pharmaceuticals

Wellesley Pharmaceuticals

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.

Book a Conference Call
Get More Information

Wellesley Pharmaceuticals

Location: Newtown, PA

Sector: Life Sciences

.

Add to Shortlist
Express Interest

Wellesley Pharmaceuticals, LLC was founded to ensure that the ability of Nocturol™ to reduce and sometimes eliminate nocturia symptoms can be disseminated to help the hundreds of millions of people who can benefit from it.   Nocturol is a drug to treat nocturia, the frequent need to urinate at night.  This sometimes-deadly condition afflicts 2.4 billion people and causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage, and deadly falls.

Business Documents

MG cp Summary

Huge unmet medical need – 2.4 billion people suffer from nocturia, which causes insomnia, fatigue, depression, lower quality of life, higher rates of heart disease, stroke, long term brain damage and deadly falls.

 

No viable competition – There is one FDA approved drug to treat nocturia and it demonstrated a 0.2 void/night benefit compared to the placebo.  Our result was 4.5 times better than that. Their drug has a black box warning about the dangers of hyponatremia.  We had zero side effects reported even among patients using 2 or 3 times the recommended dose.

 

Strong patent portfolio – Our patent lawyer had been named one of the top 1000 patent lawyers in the world six years in a row.  Dr. Ping Wang has never had a patent even challenged, much less overturned.  Our patents include doses ranging from 5mg (which is useless) to 2000mg (which could be deadly).  We believe we have a huge wall of IP around our invention.

Instant efficacy – Our drug is to be taken 30 minutes before bedtime since it is effective in 30 minutes.

 

Lack of side effects – We are using about 20% of the recommended daily dose of the two component drugs for a 10-year-old child.  If it is safe for a 10-year-old to take 5 times per day, we think it should be very safe for most adults to take once per night.

 

Superior efficacy – Compared to placebo, our clinical trial demonstrated 4.5 times higher efficacy than the only FDA approved drug for nocturia.

 

High profit margins – As an LLC, we pay no corporate income tax.  As a virtual corporation, we have almost no overhead expenses.  We have only one full time employee.  We expect net income margins to approach 95% of revenue.

David A. Dill, CEO and President

David Dill is the inventor of Nocturol and the founder of Wellesley Pharmaceuticals, LLC.  Nine years ago he made six changes in his life and since then has over 100 inventions.  When he realized that one of them could have a major impact on the world, he left his CFO position to focus fulltime on nocturia, which killed his father-in-law and leads to thousands of deaths per day.   He graduated summa cum laude from Princeton University in 1973 with a degree in economics.  He graduated from MIT’s Sloan School of Management in 1975 with a Master’s degree in finance and marketing.   He spent 19 years at IBM rising to CFO of a $2 billion business unit.  Since then he was VP Finance at General Instrument and CFO at 7 venture backed companies in 7 different industries, including Worldgate Communications, PlasticsNet, StorageApps, Digital 5, Telewares, Orchestria, and Undertone.   Key Career Milestones Achieved: One IPO (Worldgate Communications in 1999), one sale of a company for $350 million (StorageApps sold to HP in 2001), over 100 inventions in the last 9 years.


Nativis Inc.

Nativis Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Nativis Inc.

Location: Seattle, Washington

Sector: Life Sciences

.

Add to Shortlist
Express Interest

Nativis has invented a groundbreaking therapeutic device technology that uses ultra-low radio frequency energy (ulRFE®) to interrupt disease mechanisms on the molecular and genetic levels – without chemicals or radiation. Nativis ulRFE is able to replicate the biological activity of a broad range of molecules including proven drugs, siRNA, mRNA, and endogenous compounds like hormones.  The resulting therapeutic product profile provides localized delivery of a proven mechanism of action, avoiding systemic toxicity, and allowing for cost-effective combination therapy (multiple targets on one device).  The therapeutic benefit is delivered via a simple-to-use investigational device called Nativis Voyager®, pictured below.  The controller weighs 6 ounces and the coil can be shaped to deliver the ulRFE® field to the desired areas of the body, avoiding exposure of other organs to maximize safety.

Business Documents

MG cp Summary

First breakthrough therapy in brain cancer – Most drugs don’t penetrate the blood brain barrier, consequently brain cancer drugs have not improved GBM outcomes in over 20 years. Nativis uniquely treats brain cancer in a way that minimizes safety and has potential to improve survival to unprecedented extent.

 

Fast to market HDE pathway – From identifying an HDE opportunity to regulatory submission takes roughly six months for Nativis, leveraging our ability to mimic existing mechanisms and rapidly enter preclinical and clinical testing.  From FDA submission to approval is roughly 6 months so the entire process takes about a year, dramatically less than a drug pathway.

 

Unique approach to cancer immunotherapy – The immuno-oncology (I/O) market is exploding, from $6 billion sales in 2017 to more than $20 billion forecasted within 5 years.  I/O drugs are not able to pass the blood-brain barrier and have significant toxicity issues.  Voyager provides localized therapy minimising toxicity, while leveraging the industry’s identification of key I/O targets (e.g. PD1, PDL1, CTLA4) for rapid progress into clinical trials.  Voyager has already been used to treat 9 patients using anti-PD1 and anti-CTLA4 mechanisms, moving much faster and less expensively than a comparable drug program.

 

Ability to leapfrog current cancer therapeutics – Cancer experts are agreed that combination therapy is critical.  Voyager uniquely can deliver combination therapy (multiple mechanisms played sequentially on a single device) in a way that is cost-effective and minimizes systemic side effects.

 

Beyond cancer, rapid entry to pain, inflammation, and other therapeutic areas – Nativis has identified opportunities in pain, inflammation, and infectious diseases where there are large markets with unmet needs that match up with the Voyager platform advantages.  For example the global anti-TNF drug market (treating arthritis and other inflammatory diseases) is over $40 billion and would be bigger if it were not held back by patient concerns about chronic immuno-suppression side effects.  Voyager has potential to deliver anti-TNF mechanism without immunosuppression, as well as providing localized pain relief.

 

Multiple vertical opportunities beyond human health – Nativis Voyager has been tested in over 300 dogs with naturally occurring cancers, showing promising signs of efficacy in over 20 tumor types.  Discussions are underway with veterinary health companies who are interested in licensing Voyager for companion animal cancer.  A joint research program is underway with an AgBio company that is testing how Nativis technology can revolutionize plant and livestock agribusiness.  Nativis has demonstrated the ability to increase lipid production in algae culture, resulting in interest from industrial biotech companies.  In all these areas beyond human health, Nativis will not invest its own money in R&D – instead the partners who identify opportunities will pay for the R&D and commercialization, with business impact accretive to Nativis.

Our initial focus is on the treatment of patients with brain cancer who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects.  Initial results from the human clinical trial (n=64) of Nativis Voyager® device in recurrent glioblastoma multiforme (rGBM) brain tumors has shown no device-related adverse events and promising signs of efficacy.  The company completed its first licensing agreement for this indication in April 2017 with Teijin Pharma, a large Japanese pharma company, and discussions continue regarding additional ulRFE® licenses to treat other conditions in Japan.  Other licensing discussions are underway with multiple global pharmaceutical companies.   In addition to GBM, Nativis is pursuing three rare pediatric brain cancers in the US (medulloblastoma, diffuse midline glioma, and ependymoma) through an accelerated FDA pathway called Humanitarian Device Exemption (HDE).  We expect to have FDA approval for these three indications by end of year 2018 and to have our first commercial revenue in early 2019, with the potential to reach $100 million in revenue in these three indications alone by 2022.  Nativis is targeting one to two HDE approvals per year for the foreseeable future, with HDE revenues totaling $200 million by 2023.

Chris E. Rivera – President, Chief Executive Officer and Chairman of the Board

Chris brings more than 30 years of experience in the biotechnology industry. Chris was the Founder and CEO of Hyperion Therapeutics, which was acquired by Horizon Pharma in 2015, the Senior Vice President and head of Commercial Operations at both Tercica, where he led the cross-licensing transaction between Tercica and Ipsen, and Genzyme Therapeutics, where he built and ran Genzyme’s US renal Commercial Operations, he also helped launch Genzyme’s renal division globally. Prior to Genzyme, he helped build Cephalon and Centocor’s initial commercial infrastructures.

 

Kenneth Ferguson, PhD – Chief Scientific Officer

Ken is Chief Scientific Officer at Nativis. Prior to joining Nativis, Ken was vice president and chief development officer at Omeros Corporation, CEO of VacTX, and spent 16 years at ICOS Corporation in research and development, where he was Product Development Team Leader and later the Chief Scientific Officer and Board member of the Lilly ICOS Joint Venture. Ken is a graduate of Cornell University and The University of Texas Health Science Center at Dallas. His doctoral research with Dr. Al Gilman focused on signal transduction, specifically the mechanism by which G proteins participate in the action of G protein-coupled receptors. Ken completed post-doctoral studies with Dr. Michael Wigler at Cold Spring Harbor Laboratory with a focus on oncogenes and the cell cycle.

 

Xavier A. Figueroa, PhD – Director, Pre-clinical Development

Xavier is the principal scientist for Nativis overseeing pre-clinical research and the application of Nativis technology in multiple disease areas. He has more than 20 years of experience in basic and neurological clinical research, including Alzheimer’s research, neuron biology, cancer research, bioengineering and biophysics. He has advised emerging biotechnology companies, most notably Cytokinetics and ENG3. Xavier has also served on non-profit Scientific Advisory boards for such organizations as the Brain Health and Healing Foundation and published broadly in multiple areas of science and medicine. Xavier received his doctoral degree in Neurobiology & Behavior from the University of Washington. His doctoral training was followed by two post-doctoral fellowships within the University of Washington’s Department of Bioengineering. He is currently an affiliate assistant professor in the School of Medicine at the University of Washington.

 

David Matteson, MPH, MEd, MPA – Investor Relations and Education

David is a seasoned business leader and strategist, who has dedicated his career to advancing health innovations, services, and products into the market place. Prior to joining Nativis full time in 2012, he consulted to early- and growth-stage companies in healthcare to develop strategic plans, raise capital, craft public policy campaigns, design and implement marketing and branding programs, manage company growth and change, and foster high-performance teams at both the board and C-suite levels. As an executive coach he has worked with dozens of entrepreneurs to hone their ideas into viable business structures and lead their ventures through the volatile journey to market. David has a diverse background that spans five academic preparations and numerous executive positions across several industries. This broad base of training and experience provides a unique, integrated, and long-view perspective that is valuable when designing integrated business structures and strategies to move innovation into the market. He has a proven track record of brokering and managing multi-disciplinary teams to tackle complex business opportunities.

 

Michael Mischke-Reeds, MA – SVP of Business Development

Michael has over 25 years of leadership experience in life sciences companies, having worked as a startup biotech executive and a management consultant, specializing in biotechnology. After studying biology and management science at Stanford University, he co-founded startup companies Fast Track Systems (software to support pharmaceutical clinical development) and Chiron Informatics (disease management software for HIV). His management consulting career started at Strategic Decisions Group (world leader in pharmaceutical asset valuation and portfolio management) and then cofounded Keelin Reeds Partners (biotech-focused consulting firm offering valuation, strategy, and transaction support). Michael is currently Senior Vice President of Business Development for Nativis, where he leads partnering activities as well as strategy and valuation.

 

Donna Morgan Murray, PhD – Chief Regulatory Officer

Donna is the Chief Regulatory Officer for Nativis. A seasoned healthcare professional, she has more than 30 years of experience in the biotechnology and pharmaceutical industries. She’s authored more than 60 publications and served on several non-profit boards and organizations. Donna holds a PhD from the University of Texas Health Science Center at Houston.

 

Eric Peterson – Director of Development and Manufacturing

Eric brings more than 20 years of experience in developing, manufacturing and commercializing innovative medical devices in fast growing start-up companies. He serves as the Director of Development and Manufacturing at Nativis, where he is responsible for leading design, development and manufacturing operations with strategic partners while ensuring compliance with FDA and ISO standards.

 

Steven Pope, MA (Oxon) JD – Corporate Secretary and Sr. VP, General Counsel

Steven is responsible for overseeing the legal affairs of the Company, including contracts, securities, governance, intellectual property, and employment matters. Prior to joining Nativis in 2010, Steven was a Partner at Perkins Coie LLP. Steven received his J.D. cum laude from Seattle University School of Law where he was a member of the Law Review, his M.A. from the University of Oxford, and his B.A. summa cum laude from Gonzaga University.

 

Gabriel Vogeli, PhD – Senior Distinguished Scientist

Gabriel, Distinguished Scientist, is the former Director of Molecular Biology for Dendreon Corporation, former Senior Scientist at Upjohn Company/Pharmacia-Upjohn and Senior Staff Fellow at the National Institutes of Health. Gabriel holds a PhD from the University of Zurich, and was a Postdoctoral Fellow at Yale University.


Acera Surgical Inc.

Acera Surgical Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Acera Surgical Inc.

Location: St. Louis, MO

Sector: Life Sciences .

Add to Shortlist
Express Interest

Acera Surgical, Inc. (“Acera”) is a bioscience company commercializing a portfolio of implantable nanomedical scaffolds for regenerative medical applications.  Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus promote rapid and effective healing.  The FDA cleared Acera’s first product, Cerafix®, in March 2016 and its second product, Restrata™, in April 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue.

Business Documents

MG cp Summary

Acera is developing products that serve as resorbable scaffolds for regenerative medical applications within multiple clinical specialties, including neurosurgery, advanced wound care, breast reconstruction, and hernia repair. Acera’s initial offering, the Cerafix® Dura Substitute, is designed for use in neurosurgical procedures and is currently used in clinics throughout the US following its FDA regulatory clearance under a 510(k) application in 2016. Acera received FDA clearance for its second product, the Restrata™ Wound Matrix, in April 2017 and is initiating a soft launch in the US in 2017.

 

Acera is expanding its product portfolio by:

1) expanding clinical claims for Cerafix® within neurosurgery,

2) securing new clinical indications for the Cerafix®/ Restrata™ material in other surgical specialties, and

3) developing new material configurations to address clinical needs in targeted clinical specialties.

Competitive Advantage / Market Opportunities:

Acera has developed a portfolio of fully synthetic materials constructed from resorbable nano-scale fibers that address the shortcomings of conventional biologic and macro-scale synthetic tissue scaffolds. Due to the structural similarities between Acera’s nano-fiber scaffolds and native extracellular matrix, new cells and vasculature are better able to proliferate throughout the material and integrate into surrounding tissue, thus promoting effective tissue repair and regeneration. Acera’s products also undergo complete resorption in vivo once the tissue has regenerated and the defect has been repaired, thus eliminating the risk of long-term infection and/or scarring. The unique architecture also offers a combination of strength and flexibility for improved intraoperative handling.

The global market for Acera’s nanofabricated materials in 2020 is projected to be >$10B, growing 9% annually. Acera entered the neurosurgery market (>$150M) in 2016 and is leveraging the same material for additional clinical fields of use, including the advanced wound care market (~$1B).  In parallel, Acera is working to develop new materials for use in the hernia repair and breast reconstruction markets (>$3B).  Trends driving significant growth in these markets include aging patient populations, increasing numbers of surgical procedures, growing number of minimally invasive procedures, and entry of innovative technologies / materials.

 

Advisory Board and Strategic Partners / Go-to-Market Strategy:  

Acera’s Neurosurgical Clinical Advisory Board is comprised of five leading academic neurosurgeons, including the former Chairman of the American Association of Neurosurgeons, Dr. Ralph Dacey.  Acera’s Neurosurgical Advisory Board guided the design of the Cerafix® Dura Substitute to optimally address the unmet needs of contemporary neurosurgeons.  The Wound Healing Clinical Advisory Board is chaired by Dr. Matthew Regulski, a triple board certified foot and ankle surgeon practicing in New Jersey, the Medical Director of the Wound Care Institute of Ocean County in Toms River, NJ, and Director of the Kimball Medical Center Wound Care Center.In addition to clinical advisors, Acera is backed by a large network of experts in biomedical engineering, bio-entrepreneurship, healthcare, and business finance.

In 2015, Acera executed a distribution agreement with Mizuho America, a leading medical device stocking distributor with established sub-distributor relationships in both domestic and international neurosurgical markets, and Acera worked closely with Mizuho to successfully execute the national launch of the Cerafix® Dura Substitute. Acera has contracted with a US-based manufacturing partner with expertise in resorbable polymer technologies that will be an instrumental partner in expanding the technology into new clinical areas. Finally, Acera is in discussions with multiple strategic partners who may serve as potential end acquirers, commercialization partners for RestrataTM, and/or co-development partners.

 

Intellectual Property: 

Acera Surgical, Inc. holds exclusive rights to the proprietary technology utilized in the design, production and use of its innovative non-biologic nanofabricated products under a licensing agreement with Washington University and an intellectual property agreement with its parent company, Retectix, LLC for the following fields of use: neurosurgery, general and minimally invasive surgery, otolaryngology/head and neck surgery, plastic reconstructive surgery, obstetrics and gynecology, and soft tissue repair.  Acera’s technology is protected under 30 patent applications and 6 issued/allowed patents filed by Armstrong-Teasdale, LLP, Knobbe, Marten, Olson, and Bear, LLP, and Stinson Leonard Street LLP.  Freedom to operate opinions and landscape analyses performed by Polsinelli-Shughart, LLP and The Global Patent Group, LLP suggest Acera has freedom to operate.

Dr. Matthew MacEwan – President / Chief Scientific Officer, Board Member

Dr. Matthew is responsible for research and product development, pre-clinical/clinical testing, regulatory compliance and clinical/medical affairs at Acera Surgical, Inc.  Matthew is an MD/PhD Candidate at the Washington University School of Medicine in St. Louis, Missouri where he recently completed his PhD in Biomedical Engineering.   Matthew has received multiple awards for his scientific and entrepreneurial work in the life science community, including the 2011 Olin Cup Award (Olin School of Business, Washington University), Grand Prize at the 2011 LES Global Business Plan Competition (International Licensing Executives Society), First Place at the 2011 I2P Global Competition (I2P, University of Texas), and Top 40 Under 40 in St. Louis (St. Louis Business Journal).  Matthew graduated summa cum laude with a degree in Biomedical Engineering from Case Western Reserve University in Cleveland, Ohio with a specialization in polymer biomaterials / biomaterial biocompatibility.

 

Agnès Rey-Giraud – Chief Executive Officer, Board Member

Agnes is responsible for corporate strategy, corporate finance and business development at Acera Surgical, Inc. Agnès is a former Officer of Express Scripts, Inc., where she served in multiple roles in Product Development, Supply Chain, Corporate Strategy and International Operations. Agnès joined Express Scripts in 1999, and quickly became a driving force behind many of the company’s key strategic initiatives and an influential player in the transformation of the company from a $4 billion enterprise to a $44 billion enterprise. In her most recent role as President, International Operations, Agnès led the company’s movement into Asia. Agnès earned a Master of Science in Mechanical Engineering from Ecole Nationale d’Ingénieurs de Saint Etienne and a Master of Management in Operations Management from Ecole de Management de Lyon, both in France, as well as an MBA from the University of Chicago. Among numerous other awards and accolades, she is a 2011 St. Louis Business Journal Most Influential St. Louisan and a 2009 St. Louis YWCA Leader of Distinction.

 

Julie Cochran – Chief Operating Officer

Julie is responsible for product development, sales and marketing, business development and strategic planning, legal and regulatory affairs/compliance, finance, human resources and operations at Acera Surgical, Inc. Prior to joining Acera Surgical, Inc., Julie served multiple roles at Express Scripts, Inc., including Vice President of Strategic Planning, Vice President of Product Development, and Senior Director of e-business Product Management.  Prior to Express Scripts, Julie was a consultant at McKinsey and Company, Inc., working with biotechnology, medical device, pharmaceutical and payer organizations. Julie graduated summa cum laude with a Bachelors of Science in Engineering in both Biomedical Engineering and Electrical Engineering from Duke University and earned an MBA from the Stanford Graduate School of Business.


Biopep Solutions Inc.

Biopep Solutions Inc.

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Biopep Solutions Inc.

Location: Richmond, BC

Sector: Life Sciences

.

Add to Shortlist
Express Interest

Biopep Solutions Inc. is a private late-preclinical stage bio-tech company. Biopep’s lead candidate drug’s multivalent cancer inhibition mechanism is revolutionary in the treatment of cancer. The drug, called BPS-001, blocks the channels cancer tumors use to promote cancer survival  and their ability to grow and spread.  Rather than being limited to the short-comings of current drugs and therapies, Biopep believes that it is developing the next generation of cancer therapy that will simultaneously block the different channels of cancer growth.

Business Documents

MG cp Summary

Need for a drug that is effective against cancer resistance 

The problem with conventional drugs and therapies is that the cancer develops resistance to them over time and it returns in a more aggressive form.In comparison to the weaknesses of the current prostate cancer drugs, BPS-001 inhibits the expression of the entire androgen receptor as well as inhibiting the growth of new blood vessels, reducing inflammation and cancer cell migration, and activating cancer cell death.

 

Need for a cancer therapy with minimal side effects

Chemotherapy is toxic and has a negative impact on the quality of life for the patient. As well as being toxic, it is non-specific, meaning healthy cells are also affected. BPS-001 is non-toxic at over 160 times the normal dose in animal studies. As opposed to conventional cancer therapies, BPS-001 is administered weekly through an injection similar to insulin.

 

Need for effective late stage prostate cancer therapy

When caught early, prostate cancer is often treatable. However, the only option to advanced prostate cancer patients treatment is chemotherapy which is very toxic and only prolongs life.BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment of late stage metastatic prostate cancer (mCRPC) in comparison to existing drugs, without any significant toxic side effects, and durable treatment.

Biopep’s lead drug candidate, BPS-001, has a unique multivalent mechanism to treat various forms of cancer.  The initial target indication is prostate cancer.  However, unlike conventional therapies like chemotherapy, hormone depravation therapy or immunotherapy, BPS-001 has the following advantages:

  • A multivalent mechanism of action, which targets multiple pathways and sites on the cancer cell, which means the cancer will be unable to develop resistance to the treatment which is the case with conventional single targeted drugs;
  • Inhibits the formation of new blood vessels that feed the cancer (i.e. inhibits the process of angiogenesis);
  • Promotes the programmed death of cancer cells by a process called apoptosis;
  • Reduces inflammation which is a driver of all major diseases;
  • BPS-001 has very low toxicity giving it a large therapeutic window;
  • Ease of administration, a once weekly subcutaneous injection; and
  • BPS-001 has the potential to change the landscape of cancer therapy by providing a more effective treatment for late stage prostate cancer (mCRPC) in comparison to existing drugs and therapies.

Ahmed Merzouk, Director, President and Chief Executive Officer

Dr. Merzouk has more than 20 years’ experience in industry and academia in drug discovery of small and large molecules. The expertise of Dr. Merzouk ranges from design, synthesis, and purification of synthetic molecules to extraction of active ingredients from natural sources.

 

Yalcin Ilsever, PhD, CPA.CGA, IMA(USA),FICBDirector, Executive Vice President and Chief Financial Officer

Dr. Ilsever is a Chartered Professional Accountant (CPA). His PhD is in  Accounting, Finance and Statistical Measurement. He has extensive experience in the private sector in the issuance of fixed income securities and equities. Dr. Ilsever has also published extensively on electronic commerce platforms, and business measurement systems.

 

Gary Yalloway, PhD, Director, Vice President, Regulatory Affairs and Drug Development

Dr. Yalloway has over 22 years of multidisciplinary experience in industry and academia and skills in enzyme engineering and protein purification of proteins of medical and industrial interest. He has significant experience in regulatory affairs with both the US Food and Drug Administration and Health Canada. He is highly experienced in all aspects of R&D, process development, and the scale-up and manufacture of therapeutic proteins. His specialties include upstream and downstream processing, including large-scale production and bulk manufacturing of recombinant proteins.


Aquila Diagnostic Systems

Aquila Diagnostic Systems

Marketplace

Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Aquila Diagnostic Systems

Location: Edmonton, Alberta

Sector: Life Sciences

Add to Shortlist
Express Interest

Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.

Business Documents

MG cp Summary

Low cost technology – Ability to price Aquila products at same price as veterinarians pay today for an inferior product

 

Ability to work with any industry standard diagnostic instrument – Aquila is not building a diagnostic instrument: we are agnostic to instrument providing the customer with a wide variety of instrument options depending upon budget and requirements.

 

Patents on Aquila hydrogelStrong patents in place in a technology where such patents are extremely difficult to achieve

 

Ability to work with “dirty” samples – Aquila’s patented hydrogel provides a significant and sustainable competitive advantage with its unmatched ability to work with “dirty” samples such as milk and feces.

 

Simple or no DNA extraction required from sample – Minimizes or eliminates step when compared to conventional PCR technology. Lowers cost and time to perform test.

“ Aquila Diagnostic Systems Inc. is exploiting its patented molecular (DNA/RNA) diagnostic technology to provide a game-changing solution for the tangible and quantifiable pain caused by the poor state of diagnostics which currently exists in the large North American and European markets for companion animal (canine and feline), with plans to expand to the equine and food production markets including poultry, dairy and porcine.”

Brent James, CEO, B.Comm UBC; MBA Sloan School MIT

Brent James has a 30-year history of accomplishments in the high tech field including co-founding a company (MDSI) that went public on NASDAQ, and being the turn-around CEO of a company (Abebooks.com), which was sold to Amazon.

 

Dr. Jason Acker, Co-Founder & CTO; BSc, MSc, MBA, PhD

Dr.Jason Acker, Co-Founder and Chief Technology Officer, brings more than 15 years of experience with multinational pharmaceutical and biotechnology companies in Canada, USA, Singapore and the U.K.  Jason also managed interdisciplinary teams at the University of Alberta, Canadian Blood Services, and Harvard Medical School.

 

David Alton, Co-Founder & COO; MBA

David Alton co-Founder and Chief Operating Officer of Aquila, has extensive experience in the micro and nano technology sectors, research management and company start-ups